⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Most conversations about GLP-1 medications focus on the first few months — the initial weight loss, the side effects that come and go, the excitement of seeing the scale move. But GLP-1 medications like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are not short-term interventions. They are approved for indefinite, long-term use — and the questions that matter most for many Indian users are not "will this work?" but "will this keep working?" and "what does years on this medication actually look like?"
This guide covers what the clinical trial data and real-world evidence tells us about GLP-1 over the long term, in the Indian context.
Consult your healthcare provider before starting any medication. This article is informational only and does not replace professional medical advice.
The first year of GLP-1 therapy is typically characterised by:
| Test | Frequency | Why |
|---|---|---|
| HbA1c | Every 3 months (diabetics) | Track glucose control |
| Fasting lipid profile | Every 6 months | GLP-1 improves lipids |
| Kidney function (serum creatinine, eGFR) | Every 6 months | Monitor renal effects |
| Liver enzymes (ALT, AST) | At 3 months, then annually | Rule out liver stress |
| Vitamin B12 | At 6 months | Risk of deficiency with reduced food intake |
| Vitamin D (25-OH) | At 6 months | High baseline deficiency in India |
| Body weight + body composition | Monthly | Track lean vs fat mass |
By the end of year 1 and into year 2, most users have transitioned from active weight loss to maintenance. This phase brings different challenges and questions.
This is one of the most common concerns. The short answer: the medication does not lose efficacy at a pharmacological level. The GLP-1 receptor does not become desensitised with continuous use. What changes is:
Clinical evidence: The STEP 5 trial followed semaglutide users for 104 weeks (2 years). Weight loss continued gradually through year 1 and then plateaued, with most weight maintained through year 2. HbA1c and cardiovascular risk markers remained improved throughout.
Most users remain on their maximum dose. However:
Many users report a shift in year 2: the excitement of rapid weight loss has faded, the routine of injections is well-established, and motivation can dip. Common psychological experiences include:
Working with a dietitian or diabetes educator to refresh your nutritional approach in year 2 is one of the most evidence-backed strategies for maintaining momentum.
Long-term extension studies beyond 2 years are fewer, but the SELECT trial (semaglutide for cardiovascular risk reduction) ran for approximately 3.3 years in a large cardiovascular population. Findings:
The SCALE Maintenance trial (liraglutide) showed that users who continued liraglutide for 3 years maintained significantly more weight loss than those who stopped.
Side effects typically improve significantly after the first year. Long-term users report:
| Product | Monthly Cost (India, 2026) |
|---|---|
| Ozempic 0.5 mg (Novo Nordisk) | ~₹10,000–₹12,000 |
| Ozempic 1.0 mg (Novo Nordisk) | ~₹12,000–₹15,000 |
| Victoza 1.2 mg (liraglutide) | ~₹8,000–₹10,000 |
| Generic semaglutide (Sun Pharma — Semafit/equivalent) | ~₹3,000–₹5,000 |
Over 5 years, branded GLP-1 therapy costs ₹6–₹9 lakh. Generic Indian versions have reduced costs significantly since 2024–2025.
Long-term GLP-1 use is appropriate when:
Consider discussing stopping with your doctor if:
What happens when you stop: Most users experience some weight regain — typically 50–70% of lost weight returns within 12 months of stopping without continued lifestyle intervention. This does not mean GLP-1 "failed." It reflects that obesity and type 2 diabetes are chronic conditions requiring ongoing treatment, much like hypertension or hypothyroidism.
Q: Do I need to take GLP-1 forever? A: For most users, yes — if the indication (diabetes, obesity) persists. Stopping typically leads to weight regain and glucose deterioration. Think of it the way you think of blood pressure medication — effective while taken, not a cure.
Q: Can I take breaks from GLP-1 to reduce cost? A: Some patients do use "drug holidays" — typically stopping for 2–3 months and restarting. Clinical data on this approach is limited. Weight and glucose typically worsen during breaks. Discuss with your doctor before doing this.
Q: Will I need the same dose in year 5 as in year 1? A: Not necessarily. Many long-term users find their maintenance dose is stable at a level below maximum. Your doctor will adjust based on ongoing clinical response.
Q: Are there better GLP-1 options coming to India? A: Tirzepatide (Mounjaro) — a dual GIP/GLP-1 agonist — was approved in India in 2024 and shows superior weight loss (~20% at 72 weeks in SURMOUNT-1). For patients who plateau on GLP-1 monotherapy, switching to tirzepatide under medical supervision is an option worth discussing.
Consult your healthcare provider before starting any medication and before making any changes to your long-term treatment plan.
